Zhu Y, Li K, Zhang J, Wang L, Sheng L, Yan L
Transl Cancer Res. 2022; 10(3):1193-1203.
PMID: 35116447
PMC: 8798347.
DOI: 10.21037/tcr-20-1760.
Lu H, Zha S, Zhang W, Wang Q, Jiang D, Xu X
BMC Cancer. 2021; 21(1):830.
PMID: 34275458
PMC: 8286600.
DOI: 10.1186/s12885-021-08441-z.
Brown K, Andreopoulou E, Andreopoulou P
Oncol Hematol Rev. 2021; 16(1):17-22.
PMID: 33841882
PMC: 8034602.
DOI: 10.17925/ohr.2020.16.1.17.
Sinn B, Fu C, Lau R, Litton J, Tsai T, Murthy R
NPJ Breast Cancer. 2019; 5:16.
PMID: 31231679
PMC: 6542807.
DOI: 10.1038/s41523-019-0111-0.
Savci-Heijink C, Halfwerk H, Koster J, Van de Vijver M
BMC Cancer. 2017; 17(1):755.
PMID: 29132326
PMC: 5683464.
DOI: 10.1186/s12885-017-3691-9.
More options, more considerations: how new treatment options influence clinical decision making.
Park I
J Thorac Dis. 2016; 8(10):E1408-E1409.
PMID: 27867642
PMC: 5107477.
DOI: 10.21037/jtd.2016.10.63.
Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer.
Kiba T, Morii N, Takahashi H, Ozaki S, Atsumi M, Masumoto F
Mol Clin Oncol. 2016; 4(1):47-50.
PMID: 26870356
PMC: 4727054.
DOI: 10.3892/mco.2015.668.
The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.
Song Q, Zhou X, Yu J, Dong N, Wang X, Yang H
Sci Rep. 2015; 5:16775.
PMID: 26602960
PMC: 4658481.
DOI: 10.1038/srep16775.
Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion.
Gnant M, Greil R, Hubalek M, Steger G
Breast Care (Basel). 2014; 8(4):293-9.
PMID: 24415983
PMC: 3808223.
DOI: 10.1159/000354121.
Radiofrequency ablation of metastatic lesions from breast cancer.
Bortolotto C, Macchi S, Veronese L, Dore R, Draghi F, Rossi S
J Ultrasound. 2013; 15(3):199-205.
PMID: 23459396
PMC: 3558106.
DOI: 10.1016/j.jus.2012.06.007.
Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.
OShaughnessy J, Kaufmann M, Siedentopf F, Dalivoust P, Debled M, Robert N
Oncologist. 2012; 17(4):476-84.
PMID: 22418569
PMC: 3336834.
DOI: 10.1634/theoncologist.2011-0281.
Brain metastases free survival differs between breast cancer subtypes.
Berghoff A, Bago-Horvath Z, de Vries C, Dubsky P, Pluschnig U, Rudas M
Br J Cancer. 2012; 106(3):440-6.
PMID: 22233926
PMC: 3273356.
DOI: 10.1038/bjc.2011.597.
Targeting invadopodia to block breast cancer metastasis.
Eckert M, Yang J
Oncotarget. 2011; 2(7):562-8.
PMID: 21725138
PMC: 3248174.
DOI: 10.18632/oncotarget.301.
Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer.
Onishi H, Morisaki T, Nakafusa Y, Nakashima Y, Yokohata K, Katano M
Int J Clin Oncol. 2011; 16(6):718-21.
PMID: 21327450
DOI: 10.1007/s10147-011-0195-5.
Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer.
Cobham M, Donovan D
Cancer Manag Res. 2010; 1:69-77.
PMID: 21188125
PMC: 3004658.
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel.
Steger G, Abrahamova J, Bacanu F, Brincat S, Brize A, Cesas A
Wien Klin Wochenschr. 2010; 122(11-12):368-79.
PMID: 20549373
DOI: 10.1007/s00508-010-1373-6.
Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.
Andre F, Broglio K, Pusztai L, Berrada N, Mackey J, Nabholtz J
Oncologist. 2010; 15(5):476-83.
PMID: 20421265
PMC: 3227977.
DOI: 10.1634/theoncologist.2009-0150.
Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index.
Liu M, Huang W, Wang A, Huang C, Huang C, Chang T
Support Care Cancer. 2009; 18(12):1553-64.
PMID: 19904562
DOI: 10.1007/s00520-009-0778-0.
Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.
Miles D
Breast Cancer Res. 2009; 11(4):208.
PMID: 19744307
PMC: 2750099.
DOI: 10.1186/bcr2237.
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
Cardoso F, Bedard P, Winer E, Pagani O, Senkus-Konefka E, Fallowfield L
J Natl Cancer Inst. 2009; 101(17):1174-81.
PMID: 19657108
PMC: 2736293.
DOI: 10.1093/jnci/djp235.
